Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate RAPT Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding RAPT Therapeutics, Inc.’s stock price such as:

• RAPT Therapeutics, Inc.’s current stock price and volume
• Why RAPT Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RAPT from analysts
• RAPT’s stock price momentum as measured by its relative strength

About RAPT Therapeutics, Inc. (RAPT)

Before we jump into RAPT Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Want to learn more about RAPT Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about RAPT Therapeutics, Inc..

RAPT Therapeutics, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, RAPT Therapeutics, Inc.’s stock price was $33.260.

RAPT Therapeutics, Inc. is up 10.98% from its previous closing price of $29.970.

During the last market session, RAPT Therapeutics, Inc.’s stock traded between $29.755 and $34.460. Currently, there are approximately 26.96 million shares outstanding for RAPT Therapeutics, Inc..

RAPT Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

RAPT Therapeutics, Inc. Stock Price History

RAPT Therapeutics, Inc.’s (RAPT) price is currently up 10.1% so far this month.

During the month of November, RAPT Therapeutics, Inc.’s stock price has reached a high of $34.460 and a low of $26.500.

Over the last year, RAPT Therapeutics, Inc. has hit prices as high as $42.392 and as low as $5.665. Year to date, RAPT Therapeutics, Inc.’s stock is up 163.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused RAPT Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 25, 2025, there was 1 analyst who downgraded RAPT Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate RAPT Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on RAPT Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about RAPT Therapeutics, Inc. (RAPT) by visiting AAII Stock Evaluator.

Relative Price Strength of RAPT Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 25, 2025, RAPT Therapeutics, Inc. has a weighted four-quarter relative price strength of 66.03%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how RAPT Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

RAPT Therapeutics, Inc. Stock Price: Bottom Line

As of November 26, 2025, RAPT Therapeutics, Inc.’s stock price is $33.260, which is up 10.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like RAPT Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.